1.52
0.65%
-0.01
After Hours:
1.52
Milestone Pharmaceuticals Inc stock is traded at $1.52, with a volume of 65,068.
It is down -0.65% in the last 24 hours and up +7.04% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.53
Open:
$1.54
24h Volume:
65,068
Relative Volume:
0.59
Market Cap:
$81.24M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.1095
EPS:
-1.37
Net Cash Flow:
$-46.54M
1W Performance:
-0.98%
1M Performance:
+7.04%
6M Performance:
-15.08%
1Y Performance:
-50.97%
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
Mar-05-21 | Initiated | H.C. Wainwright | Buy |
Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
Jun-04-19 | Initiated | Oppenheimer | Outperform |
Jun-03-19 | Initiated | Cowen | Outperform |
Jun-03-19 | Initiated | Jefferies | Buy |
Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Grows By 17.6% - MarketBeat
NRX-100 (Ketamine) Reaches Stability Milestone - Contract Pharma
Milestone Pharmaceuticals to Host Investor KOL Event - StockTitan
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 0.7% Higher - Defense World
Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price Up 0.7% - MarketBeat
Delaware Court of Chancery Finds Buyer Failed to Use Commercially Reasonable Efforts in Pharma Milestone Payment Case - The Harvard Law School Forum on Corporate Governance
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease - StockTitan
Citius Pharmaceuticals defers FDA milestone payment - Investing.com
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
TD Cowen holds Buy on Milestone Pharmaceuticals stock, expects peak sales of $441M - Investing.com
TD Cowen holds Buy on Milestone Pharmaceuticals stock, expects peak sales of $441M - Investing.com Canada
TD Cowen holds Buy on Milestone Pharmaceuticals stock, expects peak sales of $441M - Investing.com India
Hemogenyx Pharmaceuticals passes crucial milestone ahead of phase I trial - Proactive Investors UK
Etripamil nasal spray shows promise in China trial By Investing.com - Investing.com Australia
Etripamil nasal spray shows promise in China trial By Investing.com - Investing.com Canada
Etripamil nasal spray shows promise in China trial - Investing.com
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China - GlobeNewswire Inc.
Milestone Pharmaceuticals welcomes new board member Joseph Papa - Investing.com
Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration - Business Wire
Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80 - Yahoo Finance
Brokers Offer Predictions for Milestone Pharmaceuticals Inc.'s FY2024 Earnings (NASDAQ:MIST) - MarketBeat
Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024 - StockTitan
HC Wainwright Analysts Lower Earnings Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals (NASDAQ:MIST) Given “Buy” Rating at HC Wainwright - Defense World
Rodman & Renshaw Initiates Coverage of Milestone Pharmaceuticals (MIST) with Buy Recommendation - MSN
HC Wainwright Reaffirms "Buy" Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from Analysts at Rodman & Renshaw - MarketBeat
Milestone stock wins Buy at Rodman Renshaw (NASDAQ:MIST) - Seeking Alpha
Milestone Pharmaceuticals (NASDAQ:MIST) Coverage Initiated at Rodman & Renshaw - Defense World
Thinking about buying stock in Cellebrite DI, Milestone Pharmace - GuruFocus.com
Thinking about buying stock in Mogo Inc, Rigetti Computing, Apte - GuruFocus.com
Milestone Pharmaceuticals: Q2 Earnings Snapshot - CTPost
MISTMilestone Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Milestone Pharmaceuticals: Q2 Earnings Snapshot - CT Insider
Milestone Pharmaceuticals: Q2 Earnings Snapshot - San Antonio Express-News
Milestone Pharmaceuticals: Q2 Earnings Snapshot - San Francisco Chronicle
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - wallstreet:online
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - StockTitan
Agios Pharmaceuticals' Shares Rise Ahead of $1.1B in Milestone Payments - MarketWatch
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib - StockTitan
Contrasting AstraZeneca (NASDAQ:AZN) & Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World
SIPP Industries Announces Milestone Achievements in Partnership with Calypso Pharmaceuticals - StockTitan
Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference - StockTitan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stake Boosted by BNP Paribas Financial Markets - Defense World
Mirum Pharmaceuticals hits all-time high at $40.76, marking a significant milestone - Investing.com India
Mirum Pharmaceuticals hits all-time high at $40.76, marking a significant milestone - Investing.com Nigeria
Mirum Pharmaceuticals hits all-time high at $40.76, marking a significant milestone - Investing.com
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 2.7% Higher - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 2.7% Higher - Defense World
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties - GlobeNewswire
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):